These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 11342196)

  • 21. From the Broad Phase II Trial to Precision Oncology: A Perspective on the Origins of Basket and Umbrella Clinical Trial Designs in Cancer Drug Development.
    Doroshow DB; Doroshow JH
    Cancer J; 2019; 25(4):245-253. PubMed ID: 31335388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Size-Dependent Segregation Controls Macrophage Phagocytosis of Antibody-Opsonized Targets.
    Bakalar MH; Joffe AM; Schmid EM; Son S; Podolski M; Fletcher DA
    Cell; 2018 Jun; 174(1):131-142.e13. PubMed ID: 29958103
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic antitumor activity by combining trastuzumab with retinoic acid in HER2 positive human breast cancer cells.
    Vanderhoeven F; Redondo AL; Martinez AL; Vargas-Roig LM; Sanchez AM; Flamini MI
    Oncotarget; 2018 May; 9(41):26527-26542. PubMed ID: 29899874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and Evaluation of Tri-Functional Immunoliposomes for the Treatment of HER2 Positive Breast Cancer.
    Vaidya T; Straubinger RM; Ait-Oudhia S
    Pharm Res; 2018 Mar; 35(5):95. PubMed ID: 29536232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting protein quality control pathways in breast cancer.
    Sannino S; Brodsky JL
    BMC Biol; 2017 Nov; 15(1):109. PubMed ID: 29145850
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selection of a Novel Aptamer Against Vitronectin Using Capillary Electrophoresis and Next Generation Sequencing.
    Stuart CH; Riley KR; Boyacioglu O; Herpai DM; Debinski W; Qasem S; Marini FC; Colyer CL; Gmeiner WH
    Mol Ther Nucleic Acids; 2016 Nov; 5(11):e386. PubMed ID: 27845768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Decoration of pH-sensitive copolymer micelles with tumor-specific peptide for enhanced cellular uptake of doxorubicin.
    Chen Q; Long M; Qiu L; Zhu M; Li Z; Qiao M; Hu H; Zhao X; Chen D
    Int J Nanomedicine; 2016; 11():5415-5427. PubMed ID: 27799766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Examining the protective role of ErbB2 modulation in human-induced pluripotent stem cell-derived cardiomyocytes.
    Eldridge S; Guo L; Mussio J; Furniss M; Hamre J; Davis M
    Toxicol Sci; 2014 Oct; 141(2):547-59. PubMed ID: 25055963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling.
    Pruszynski M; Koumarianou E; Vaidyanathan G; Revets H; Devoogdt N; Lahoutte T; Lyerly HK; Zalutsky MR
    J Nucl Med; 2014 Apr; 55(4):650-6. PubMed ID: 24578241
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiac-specific over-expression of epidermal growth factor receptor 2 (ErbB2) induces pro-survival pathways and hypertrophic cardiomyopathy in mice.
    Sysa-Shah P; Xu Y; Guo X; Belmonte F; Kang B; Bedja D; Pin S; Tsuchiya N; Gabrielson K
    PLoS One; 2012; 7(8):e42805. PubMed ID: 22912742
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improving survival and limiting toxicity: latest advances in treating human epidermal growth factor receptor 2 overexpressing breast cancer.
    Abramson VG; Mayer IA
    Ther Adv Med Oncol; 2012 May; 4(3):139-47. PubMed ID: 22590487
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of HER2-positive metastatic breast cancer following initial progression.
    Mayer IA
    Clin Breast Cancer; 2009 Jun; 9 Suppl 2(Suppl 2):S50-7. PubMed ID: 19596643
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transfer of Her-2/neu specificity into cytokine-induced killer (CIK) cells with RNA encoding chimeric immune receptor (CIR).
    Yoon SH; Lee JM; Woo SJ; Park MJ; Park JS; Kim HS; Park MY; Sohn HJ; Kim TG
    J Clin Immunol; 2009 Nov; 29(6):806-14. PubMed ID: 19517218
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer.
    Jin Q; Esteva FJ
    J Mammary Gland Biol Neoplasia; 2008 Dec; 13(4):485-98. PubMed ID: 19034632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DNA array-based gene profiling: from surgical specimen to the molecular portrait of cancer.
    Mocellin S; Provenzano M; Rossi CR; Pilati P; Nitti D; Lise M
    Ann Surg; 2005 Jan; 241(1):16-26. PubMed ID: 15621987
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells.
    Menendez JA; Vellon L; Mehmi I; Oza BP; Ropero S; Colomer R; Lupu R
    Proc Natl Acad Sci U S A; 2004 Jul; 101(29):10715-20. PubMed ID: 15235125
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical trials of Herceptin(R) (trastuzumab).
    Baselga J
    Eur J Cancer; 2001 Jan; 37 Suppl 1():18-24. PubMed ID: 11342196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical trials of Herceptin(trastuzumab).
    Baselga J
    Eur J Cancer; 2001 Jan; 37 Suppl 1():S18-24. PubMed ID: 11167087
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ; Goodin S
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trastuzumab: new indication. Metastatic breast cancer, in combination with docetaxel: promising, but more evaluation is needed.
    Prescrire Int; 2006 Feb; 15(81):3-5. PubMed ID: 16548094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.